155 related articles for article (PubMed ID: 38363526)
21. Fiscal analysis of the pediatric immunization program in Belgium applying a lifetime government perspective framework.
Kotsopoulos N; Bento-Abreu A; Bencina G; Connolly MP
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):437-445. PubMed ID: 38231471
[TBL] [Abstract][Full Text] [Related]
22. The Fiscal Consequences Attributed to Changes in Morbidity and Mortality Linked to Investments in Health Care: A Government Perspective Analytic Framework.
Connolly MP; Kotsopoulos N; Postma MJ; Bhatt A
Value Health; 2017 Feb; 20(2):273-277. PubMed ID: 28237208
[TBL] [Abstract][Full Text] [Related]
23. The fiscal consequences of ADHD in Germany: a quantitative analysis based on differences in educational attainment and lifetime earnings.
Kotsopoulos N; Connolly MP; Sobanski E; Postma MJ
J Ment Health Policy Econ; 2013 Mar; 16(1):27-33. PubMed ID: 23676413
[TBL] [Abstract][Full Text] [Related]
24. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
Ekpu VU; Brown AK
Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
[TBL] [Abstract][Full Text] [Related]
25. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
26. Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK.
Connolly M; Gallo F; Hoorens S; Ledger W
Hum Reprod; 2009 Mar; 24(3):626-32. PubMed ID: 19056775
[TBL] [Abstract][Full Text] [Related]
27. Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework.
Kotsopoulos N; Connolly MP; Remy V
Health Econ Rev; 2015 Dec; 5(1):54. PubMed ID: 26198884
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States.
Sussell J; Singh Jhuti G; Antao V; Herrera-Restrepo O; Wehler E; Bilir SP
Am J Clin Oncol; 2021 Jul; 44(7):340-349. PubMed ID: 34151896
[TBL] [Abstract][Full Text] [Related]
29. Costs and benefits of individuals conceived after IVF: a net tax evaluation in The Netherlands.
Moolenaar LM; Connolly M; Huisman B; Postma MJ; Hompes PG; van der Veen F; Mol BW
Reprod Biomed Online; 2014 Feb; 28(2):239-45. PubMed ID: 24365025
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada.
Younis T; Lee A; Coombes ME; Bouganim N; Becker D; Revil C; Jhuti GS
Curr Oncol; 2020 Dec; 27(6):e578-e589. PubMed ID: 33380873
[TBL] [Abstract][Full Text] [Related]
31. Estimating the government public economic benefits attributed to investing in assisted reproductive technology: a South African case study.
Connolly MP; Panda S; Mburu G; Matsaseng T; Kiarie J
Reprod Biomed Soc Online; 2021 Mar; 12():14-21. PubMed ID: 33033757
[TBL] [Abstract][Full Text] [Related]
32. Long-term fiscal implications of subsidizing in-vitro fertilization in Sweden: a lifetime tax perspective.
Svensson A; Connolly M; Gallo F; Hägglund L
Scand J Public Health; 2008 Nov; 36(8):841-9. PubMed ID: 19004901
[TBL] [Abstract][Full Text] [Related]
33. The 2023 Latin America report of the
Hartinger SM; Palmeiro-Silva YK; Llerena-Cayo C; Blanco-Villafuerte L; Escobar LE; Diaz A; Sarmiento JH; Lescano AG; Melo O; Rojas-Rueda D; Takahashi B; Callaghan M; Chesini F; Dasgupta S; Posse CG; Gouveia N; Martins de Carvalho A; Miranda-Chacón Z; Mohajeri N; Pantoja C; Robinson EJZ; Salas MF; Santiago R; Sauma E; Santos-Vega M; Scamman D; Sergeeva M; Souza de Camargo T; Sorensen C; Umaña JD; Yglesias-González M; Walawender M; Buss D; Romanello M
Lancet Reg Health Am; 2024 May; 33():100746. PubMed ID: 38800647
[TBL] [Abstract][Full Text] [Related]
34. Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy.
Williamson M; Press DJ; Hansen SA; Tomar A; Jhuti GS; Revil C; Gururaj K
Breast Cancer; 2024 Jan; 31(1):84-95. PubMed ID: 37907759
[TBL] [Abstract][Full Text] [Related]
35. Long-term economic benefits attributed to IVF-conceived children: a lifetime tax calculation.
Connolly MP; Pollard MS; Hoorens S; Kaplan BR; Oskowitz SP; Silber SJ
Am J Manag Care; 2008 Sep; 14(9):598-604. PubMed ID: 18778175
[TBL] [Abstract][Full Text] [Related]
36. The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic Framework.
Martins R; Kadakia A; Williams GR; Milanovic S; Connolly MP
J Clin Psychiatry; 2023 Aug; 84(5):. PubMed ID: 37555674
[No Abstract] [Full Text] [Related]
37. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L
JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431
[TBL] [Abstract][Full Text] [Related]
38. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Li J; Wang S; Wang Y; Wang X; Wang H; Feng J; Zhang Q; Sun T; Ouyang Q; Yin Y; Liu Y; Geng C; Yan M; Jiang Z
Oncologist; 2017 Nov; 22(11):1333-1338. PubMed ID: 28798274
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
40. Investing in the Prevention of Communicable Disease Outbreaks: Fiscal Health Modelling-The Tool of Choice for Assessing Public Finance Sustainability.
van der Schans S; Schöttler MH; van der Schans J; Connolly MP; Postma MJ; Boersma C
Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
